Niacin
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Ludwig-Maximilians - University of Munich
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01239992CT.gov Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia | — | Terminated | — | — | — |
NCT00286234CT.gov Niacin, N-3 Fatty Acids and Insulin Resistance | — | Completed | — | — | — |
NCT00659321CT.gov Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome | — | Completed | — | — | — |
NCT00346970CT.gov The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study) | — | Completed | — | — | — |
NCT00300365CT.gov Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL | — | Completed | — | — | — |
NCT00246376CT.gov Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia | — | Completed | — | — | — |
NCT00304993CT.gov Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niacin (this asset) | Ludwig-Maximilians - University of Munich | Approved | BB · 68 |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Amlodipine | Italo Biaggioni | P4 | BB |
| Ezetimibe | Samsung Medical Center | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Niacin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Coronary Artery Disorder | — | P4 | BB · 68 |
| Inherited Lipid Metabolism Disorder | — | P4 | BB · 68 |
| Stroke Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niacin in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niacin-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →